RxDoctor Payments Data

John Siano, MD

Internal Medicine · Lansing, MINPI 1689628067

Payments from drug & device makers

$10,341in general payments, 2019–2025

Across 650 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$1K
  • Lilly USA, LLC$856
  • AbbVie$817
  • Amgen$677
  • GSK$543
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$10,333100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk71$1,111
Pfizer66$1,044
Lilly USA, LLC64$856
AbbVie(2 entities)59$817
Amgen(2 entities)45$677
GSK40$543
Boehringer Ingelheim27$531
Viiv Healthcare Company18$365
Otsuka America Pharmaceutical, Inc.15$307
Bayer17$299
Abbott15$293
Merck19$247
Biohaven Pharmaceutical Holding Company Ltd.13$233
Novartis14$220
Biohaven Pharmaceuticals, Inc.14$207
E.r. Squibb & Sons, L.L.C.13$200
Amarin Pharma, Inc.13$199
AstraZeneca(2 entities)11$169
Mallinckrodt Hospital Products Inc.5$155
Kowa Pharmaceuticals America, Inc.11$142
Xeris Pharmaceuticals, Inc.7$133
Eisai Inc.6$127
Jazz Pharmaceuticals Inc.6$92
Nestle Healthcare Nutrition Inc.6$88
Astellas Pharma US Inc3$82
Exact Sciences5$77
Johnson & Johnson5$71
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$68
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$64
Teva Pharmaceuticals USA, Inc.4$51
Melinta Therapeutics, LLC3$50
Paratek Pharmaceuticals, Inc.3$47
Dexcom, Inc.2$47
Corcept Therapeutics2$44
Sanofi Pasteur Inc.3$41
Averitas Pharma Inc.2$40
Sanofi-aventis U.S. LLC2$39
Agios Pharmaceuticals, Inc.2$39
Daiichi Sankyo Inc.2$37
Dynavax Technologies Corporation3$37
GRT US Holding, Inc.2$35
Axsome Therapeutics, Inc.2$35
Antares Pharma, Inc.2$34
IBSA Pharma Inc.2$32
Ultragenyx Pharmaceutical Inc.2$32
Phadia US Inc.2$30
Regeneron Healthcare Solutions, Inc.1$30
Nevro Corp.1$29
Takeda Pharmaceuticals U.S.A., Inc.1$26
Otsuka Pharmaceutical Development & Commercialization, Inc.1$20
Alnylam Pharmaceuticals Inc.1$20
Grifols USA, LLC1$19
Aimmune Therapeutics, Inc.1$17
UCB, Inc.1$15
Gilead1$15
Phathom Pharmaceuticals, Inc.1$14
Sonex Health, Inc.1$14
Boston Scientific1$13
Esperion Therapeutics, Inc.1$12
Nabriva Therapeutics, PLC1$11

How this compares

$10,341 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$54,307
Medicare patients
242
Services billed
880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide219$394,760
FarxigaDapagliflozin Propanediol158$178,623
JardianceEmpagliflozin94$131,794
EliquisApixaban107$125,272
TrulicityDulaglutide54$97,828
XareltoRivaroxaban33$49,368
RybelsusSemaglutide21$37,357
MounjaroTirzepatide13$22,824
RexultiBrexpiprazole15$21,031
MyrbetriqMirabegron18$18,209
EntrestoSacubitril/Valsartan13$13,080
Icosapent Ethyl17$11,395
SymbicortBudesonide/Formoterol Fumarate14$7,529
Tresiba Flextouch U-200Insulin Degludec12$7,243
Atorvastatin Calcium419$6,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,111$432,117240 claims
AstraZenecaFarxiga, Symbicort$169$186,151172 claims
Boehringer IngelheimJardiance, Stiolto Respimat$531$138,283106 claims
PfizerEliquis$1,044$125,272107 claims
Lilly USA, LLCTrulicity, Mounjaro$856$120,65267 claims
Johnson & JohnsonXarelto$71$49,36833 claims
Otsuka America Pharmaceutical, Inc.Rexulti$307$21,03115 claims
Astellas Pharma US IncMyrbetriq$82$18,20918 claims
NovartisEntresto$220$13,08013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →